| Product Name |
Recombinant Human PPARG Protein |
| Product Overview |
This recombinant human PPARG protein includes amino acids 209-477aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
P37231 |
| Recommended Name |
Peroxisome proliferator-activated receptor gamma |
| Gene Name |
PPARG |
| Synonyms |
Peroxisome proliferator-activated receptor gamma, NR1C3, CIMT1, GLM1, NR1C3, PPARG1, PPARG2, PPARgam |
| Species |
Human |
| Predicted Molecular Mass |
33.0 kDa |
| Expression System |
E.coli |
| Expression Range |
209-477aa |
| Tag |
N-6His |
| Purity |
>90% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Transcription |
| Target Function |
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels.; (Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein. |
| Subcellular Location |
Nucleus. Cytoplasm. Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation. |
| Protein Family |
Nuclear hormone receptor family, NR1 subfamily |
| Associated Diseases |
Obesity (OBESITY); Lipodystrophy, familial partial, 3 (FPLD3); Glioma 1 (GLM1) |
| Tissue Specificity |
Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary. |
